AzTrials
AzTrials

Rheumatoid ArthritisPhase 3NCT01232569

A Study of RoActemra/Actemra (Tocilizumab) Given Subcutaneously in Combination With Traditional DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis

A Phase 3 study testing Tocilizumab 162 mg in people with Rheumatoid Arthritis, run by Hoffmann-La Roche at 141 sites in 22 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This randomized, parallel-group, placebo-controlled, multicenter study will evaluate the reduction in disease activity and the safety of tocilizumab (RoActemra/Actemra) in combination with traditional disease-modifying anti-rheumatic drugs (DMARDs) in patients with active, moderate to severe rheumatoid arthritis. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Rheumatoid Arthritis
What is being tested?
Tocilizumab 162 mg
Type of treatment
Injection or infusion
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
656 participants
Where
141 sitesin 22 countries
Study dates
Mar 2011to Nov 2013
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Adult patients, ≥ years of age.
  • Moderate to severe rheumatoid arthritis of ≥ 6 months duration.
  • Receiving treatment on an outpatient basis.
  • Swollen joint count (SJC) ≥ 6 (66 joint count) and tender joint count (TJC)≥ 8 (68 joint count) at screening and study start.
  • On a stable dose of disease-modifying anti-rheumatic drugs for at least 8 weeks prior to study start.

Who cannot join

  • Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months following randomization.
  • Rheumatic autoimmune disease other than rheumatoid arthritis, Secondary Sjögren's Syndrome with rheumatoid arthritis is allowed.
  • Functional class IV as defined by the American College of Rheumatology (ACR) Classification of Functional Status in Rheumatoid Arthritis.
  • Diagnosis of juvenile idiopathic arthritis or juvenile rheumatoid arthritis and/or rheumatoid arthritis before the age of 16 years.
  • Prior history of or current inflammatory joint disease other than rheumatoid arthritis.
  • History of malignancy, active or recurrent infections, positive to hepatitis B surface antigen or hepatitis C antibody, active tuberculosis, serious allergy to biologics, or a history of diverticular disease or other symptomatic GI conditions that might predispose to perforations.
  • Other inclusion and exclusion criteria applied to the study.

Trial locations and contacts

141 sites in 22 countries.

141 sites in 22 countries

United States44 sites
  • Study site

    Allentown, Pennsylvania, 18103

  • Study site

    Belmont, North Carolina, 28012

  • Study site

    Bethlehem, Pennsylvania, 18015

  • Study site

    Boca Raton, Florida, 33486

  • Study site

    Brooklyn, New York, 11201

  • Study site

    Charlotte, North Carolina, 28204

  • Study site

    Charlotte, North Carolina, 28207

  • Study site

    Charlotte, North Carolina, 28211

  • Study site

    Crofton, Maryland, 21114

  • Study site

    Dallas, Texas, 75246

  • Study site

    Duncansville, Pennsylvania, 16635

  • Study site

    Flowood, Mississippi, 39232

  • Study site

    Fort Worth, Texas, 76107

  • Study site

    Fullerton, California, 92835

  • Study site

    Gainesville, Georgia, 30501

  • Study site

    Hagerstown, Maryland, 21740

  • Study site

    Houston, Texas, 77034

  • Study site

    Houston, Texas, 77459

  • Study site

    Idaho Falls, Idaho, 83404

  • Study site

    Jackson, Mississippi, 39202

  • Study site

    Jupiter, Florida, 33458

  • Study site

    Lincoln, Nebraska, 68516

  • Study site

    Memphis, Tennessee, 38104

  • Study site

    Meridan, Idaho, 83642

  • Study site

    Oklahoma City, Oklahoma, 73104

  • Study site

    Ormond Beach, Florida, 32174

  • Study site

    Peoria, Arizona, 85381

  • Study site

    San Antonio, Texas, 78232

  • Study site

    San Diego, California, 92108

  • Study site

    San Leandro, California, 94578

  • Study site

    Sarasota, Florida, 34292

  • Study site

    Scottsdale, Arizona, 85258

  • Study site

    Springfield, Illinois, 62704

  • Study site

    St Louis, Missouri, 63128

  • Study site

    St Louis, Missouri, 63141

  • Study site

    Tacoma, Washington, 98405

  • Study site

    Trumbull, Connecticut, 06611

  • Study site

    Tucson, Arizona, 85723

  • Study site

    Tucson, Arizona, 85724

  • Study site

    Vernon Hills, Illinois, 60061

  • Study site

    West Hills, California, 91307

  • Study site

    Wexford, Pennsylvania, 15090

  • Study site

    Wheaton, Maryland, 20902

  • Study site

    Wyomissing, Pennsylvania, 19610

Other trials in United States

Brazil13 sites
  • Study site

    Curitiba, 80060-240

  • Study site

    Goiânia, 74043-011

  • Study site

    Juiz de Fora, 36010-570

  • Study site

    Porto Alegre, 90610-000

  • Study site

    Porto Alegre, 91350-200

  • Study site

    Rio de Janeiro, 22271-100

  • Study site

    Salvador, 40050-410

  • Study site

    São Paulo, 04026-000

  • Study site

    São Paulo, 04266-010

  • Study site

    São Paulo, 05437-010

  • Study site

    São Paulo, 1244030

  • Study site

    São Paulo, 5403900

  • Study site

    Vitória, 29055-450

Other trials in Brazil

Russia12 sites
  • Study site

    Kemerovo, 650099

  • Study site

    Moscow, 115522

  • Study site

    Moscow, 117049

  • Study site

    Moscow, 129327

  • Study site

    Novosibirsk, 630099

  • Study site

    Petrozavodsk, 185019

  • Study site

    Ryazan, 390026

  • Study site

    Saint Petersburg, 190068

  • Study site

    Saint Petersburg, 197022

  • Study site

    Saint Petersburg, 197341

  • Study site

    Ufa, 450005

  • Study site

    Voronezh, 394066

Other trials in Russia

Mexico11 sites
  • Study site

    Chihuahua City, 31000

  • Study site

    Culiacán, 80000

  • Study site

    Guadalajara, 44158

  • Study site

    León, 37320

  • Study site

    Mérida, 97000

  • Study site

    Mexicali, 21100

  • Study site

    México, 44620

  • Study site

    Morelia, 58070

  • Study site

    Obregón, 85000

  • Study site

    Querétaro, 76000

  • Study site

    Querétaro, 76178

Other trials in Mexico

Israel7 sites
  • Study site

    Ashkelon, 78306

  • Study site

    Beersheba, 84101

  • Study site

    Haifa, 31048

  • Study site

    Haifa, 31096

  • Study site

    Ramat Gan, 52621

  • Study site

    Rishon LeZiyyon

  • Study site

    Tel Aviv, 64239

Other trials in Israel

Poland7 sites
  • Study site

    Bytom, 41902

  • Study site

    Działdowo, 13-200

  • Study site

    Elblag, 82-300

  • Study site

    Kościan, 64-000

  • Study site

    Krakow, 31-121

  • Study site

    Torun, 87-100

  • Study site

    Warsaw, 02-653

Other trials in Poland

Canada6 sites
  • Study site

    Calgary, Alberta, T2N 2T9

  • Study site

    London, Ontario, N6A 4V2

  • Study site

    Ottawa, Ontario, K1H 1A2

  • Study site

    Pointe-Claire, Quebec, H9R 3J1

  • Study site

    Winnipeg, Manitoba, R3A 1M3

  • Study site

    Winnipeg, Manitoba, R3N 0K6

Other trials in Canada

Bulgaria5 sites
  • Study site

    Plovdiv, 4002

  • Study site

    Plovdiv, 4003

  • Study site

    Sofia, 1612

  • Study site

    Sofia, 2233

  • Study site

    Varna, 9010

Other trials in Bulgaria

Switzerland4 sites
  • Study site

    Fribourg, 1708

  • Study site

    Geneva, 1211

  • Study site

    Lausanne, 1011

  • Study site

    Zurich, 8063

Other trials in Switzerland

Argentina3 sites
  • Study site

    Buenos Aires, C1015ABO

  • Study site

    Córdoba, 5000

  • Study site

    San Miguel de Tucumán, 4000

Other trials in Argentina

Colombia3 sites
  • Study site

    Bogotá

  • Study site

    Chia-cundinamarca

  • Study site

    Medellín

Other trials in Colombia

Greece3 sites
  • Study site

    Athens, 11527

  • Study site

    Athens, 15121

  • Study site

    Thessaloniki, 54636

Other trials in Greece

Guatemala3 sites
  • Study site

    Guatemala City, 01010

  • Study site

    Guatemala City, 01013

  • Study site

    Guatemala City, 01015

Other trials in Guatemala

Malaysia3 sites
  • Study site

    Batu Caves, 68100

  • Study site

    Kota Kinabalu, 88586

  • Study site

    Kuala Lumpur, 50603

Other trials in Malaysia

Philippines3 sites
  • Study site

    Cebu, 6000

  • Study site

    Davao City, 8006

  • Study site

    Manila, 1780

Other trials in Philippines

South Africa3 sites
  • Study site

    Durban, 4013

  • Study site

    Pinelands, 7405

  • Study site

    Pretoria, 0002

Other trials in South Africa

Spain3 sites
  • Study site

    A Coruña, 15006

  • Study site

    Oviedo, 33006

  • Study site

    Seville, 41009

Other trials in Spain

Australia2 sites
  • Study site

    Cairns, 4870

  • Study site

    Kogarah, 2217

Other trials in Australia

Hungary2 sites
  • Study site

    Budapest, 1036

  • Study site

    Debrecen, 4004

Other trials in Hungary

Thailand2 sites
  • Study site

    Bangkok, 10400

  • Study site

    Bangkok, 10700

Other trials in Thailand

New Zealand1 site
  • Study site

    Otahuhu, 1006

Other trials in New Zealand

Panama1 site
  • Study site

    Panama City, 32400

Other trials in Panama

About this study

Official title: A Randomized, Double-blind, Parallel Group Study of Safety and the Effect on Clinical Outcome of Tocilizumab Subcutaneous (sc) Versus Placebo sc in Combination With Traditional Disease Modifying Anti-rheumatic Drugs (DMARDs) in Patients With Moderate to Severe Active Rheumatoid Arthritis

This randomized, parallel-group, placebo-controlled, multicenter study will evaluate the reduction in disease activity and the safety of tocilizumab (RoActemra/Actemra) in combination with traditional disease-modifying anti-rheumatic drugs (DMARDs) in patients with active, moderate to severe rheumatoid arthritis. In the double-blind part of the study, patients will be randomized to receive either 162 mg tocilizumab or placebo subcutaneously every 2 weeks for 24 weeks using a pre-filled syringe. In the open-label part of the study, patients will be randomized to receive 162 mg tocilizumab subcutaneously every 2 weeks from Week 24 to Week 96 using a pre-filled syringe or an auto-injector.

Being tested
Tocilizumab 162 mg, Placebo
Medical subject headings
Arthritis, Rheumatoid

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Tocilizumab 162 mgDrug

    Also called RoActemra, Actemra

    Tocilizumab will be supplied in a ready-to-use, single-use, pre-filled syringe. Patients and/or caregivers will be trained to administer the injection.

  • PlaceboDrug

    Placebo will be supplied in a ready-to-use, single-use, pre-filled syringe. Patients and/or caregivers will be trained to administer the injection.

Study groups in NCT01232569
Study groupRoleWhat they receive
Tocilizumab 162 mg scExperimentalPatients will receive tocilizumab 162 mg subcutaneously (sc) every 2 weeks for 24 weeks.
Receives: Drug: Tocilizumab 162 mg
Placebo scPlacebo comparatorPatients will receive placebo subcutaneously (sc) every 2 weeks for 24 weeks.
Receives: Drug: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Percentage of Patients With an American College of Rheumatology 20 (ACR20) Response at Week 24

    A patient had an ACR20 response if there was at least a 20% improvement, ie, reduction from baseline, in tender and swollen joint counts (28 assessed joints) and in at least 3 of the following 5 parameters: Separate patient and physician assessments of patient disease activity in the previous 24 hours on a visual analog scale (VAS, left end=no disease activity [symptom-free and no arthritis symptoms], right end=maximum disease activity; patient assessment of pain in previous 24 hours on a VAS (left end=no pain and right end=unbearable pain); Health Assessment Questionnaire-Disability Index (20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do); and acute-phase reactant (either C-reactive protein or erythrocyte sedimentation rate).

    Measured: Baseline to Week 24

Secondary outcomes (16)
  1. Percentage of Patients With ACR50 and ACR70 Responses at Week 24

    A patient had an ACR50 response if there was at least a 50% improvement in the ACR scores. A patient had an ACR70 response if there was at least a 70% improvement in the ACR scores.

    Measured: Baseline to Week 24

  2. Time to Onset of ACR20, ACR50, and ACR70 Responses

    Time to first ACR response was calculated as the number of days between the date of the first ACR response minus the date of the first dose of study drug. Median days are reported.

    Measured: Baseline to Week 24

  3. Change From Baseline in Tender Joint Count (TJC) and Swollen Joint Count (SJC) at Week 24

    Joints (28 joints) will be assessed and classified as swollen/not swollen and tender/not tender by pressure and joint manipulation on physical examination.

    Measured: Baseline to Week 24

  4. Change From Baseline in C-reactive Protein at Week 24

    Measured: Baseline to Week 24

  5. Change From Baseline in Erythrocyte Sedimentation Rate at Week 24

    Measured: Baseline to Week 24

  6. Change From Baseline in the Patient's and the Physician's Global Assessment of Disease Activity Visual Analog (VAS) Score

    Patients and physicians assessed the patient's disease activity in the previous 24 hours on a 100 mm visual analog scale, where the extreme left end of the line represented "no disease activity" (symptom-free and no arthritis symptoms) and the extreme right end represented "maximum disease activity". Scores ranged from 0 to 100 with a higher score indicating more disease activity. A negative change score indicated less disease activity.

    Measured: Baseline to Week 24

  7. Change From Baseline in the Patient's Pain Visual Analog Score

    Patients assessed their pain in the previous 24 hours on a visual analog scale, where the extreme left end of the line represented "no pain" and the extreme right end represented "unbearable pain". Scores ranged from 0 to 100 with a higher score indicating more pain. A negative change score indicated less pain.

    Measured: Baseline to Week 24

  8. Change From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 24

    The HAQ-DI is a questionnaire specific for rheumatoid arthritis and consists of 20 questions referring to 8 domains: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Patients completed the questionnaire by answering the 20 questions on a scale of 0 (without difficulty) to 3 (unable to do). The total score ranges from 0 (no disability) to 3 (completely disabled). A negative change score indicates improvement.

    Measured: Baseline to Week 24

  9. Percentage of Patients With an Improvement of ≥ 0.3 Units From Baseline in the HAQ-DI Score at Week 24

    The HAQ-DI is a questionnaire specific for rheumatoid arthritis and consists of 20 questions referring to 8 domains: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Patients completed the questionnaire by answering the 20 questions on a scale of 0 (without difficulty) to 3 (unable to do). The total score ranges from 0 (no disability) to 3 (completely disabled). A negative change score indicates improvement.

    Measured: Baseline to Week 24

  10. Change From Baseline in Disease Activity Score 28 (DAS28) at Week 24

    The DAS28 is a combined index for measuring disease activity in rheumatic arthritis (RA) and includes swollen and tender joint counts, erythrocyte sedimentation rate (ESR), and general health (GH) status. The index is calculated with the following formula: DAS28 = (0.56 × √(TJC28)) + (0.28 × √(SJC28)) + (0.7 × log(ESR)) + (0.014 × GH), where TJC28 = tender joint count and SJC28 = swollen joint count, each on 28 joints. GH = a patient's global assessment of disease activity in the previous 24 hours on a 100 mm visual analog scale (left end = no disease activity [symptom-free and no arthritis symptoms], right end = maximum disease activity [maximum arthritis disease activity]). When ESR equaled 0 mm/hr, it was set to 1 mm/hr. The DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity. A negative change score indicates improvement.

    Measured: Baseline to Week 24

  11. Percentage of Patients With a DAS28 Score ≤ 3.2 (DAS28 Low Disease Activity) at Week 24

    The DAS28 is a combined index for measuring disease activity in rheumatic arthritis (RA) and includes swollen and tender joint counts, erythrocyte sedimentation rate (ESR), and general health (GH) status. The index is calculated with the following formula: DAS28 = (0.56 × √(TJC28)) + (0.28 × √(SJC28)) + (0.7 × log(ESR)) + (0.014 × GH), where TJC28 = tender joint count and SJC28 = swollen joint count, each on 28 joints. GH = a patient's global assessment of disease activity in the previous 24 hours on a 100 mm visual analog scale (left end = no disease activity [symptom-free and no arthritis symptoms], right end = maximum disease activity [maximum arthritis disease activity]). When ESR equaled 0 mm/hr, it was set to 1 mm/hr. The DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity. A negative change score indicates improvement.

    Measured: Baseline to Week 24

  12. Percentage of Patients With a DAS28 Score < 2.6 (DAS28 Remission) at Week 24

    The DAS28 is a combined index for measuring disease activity in rheumatic arthritis (RA) and includes swollen and tender joint counts, erythrocyte sedimentation rate (ESR), and general health (GH) status. The index is calculated with the following formula: DAS28 = (0.56 × √(TJC28)) + (0.28 × √(SJC28)) + (0.7 × log(ESR)) + (0.014 × GH), where TJC28 = tender joint count and SJC28 = swollen joint count, each on 28 joints. GH = a patient's global assessment of disease activity in the previous 24 hours on a 100 mm visual analog scale (left end = no disease activity [symptom-free and no arthritis symptoms], right end = maximum disease activity [maximum arthritis disease activity]). When ESR equaled 0 mm/hr, it was set to 1 mm/hr. The DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity. A negative change score indicates improvement.

    Measured: Week 24

  13. Percentage of Patients With Good, Moderate, or no European League Against Rheumatism (EULAR) Responses at Week 24

    Change of the Disease Activity Score 28 score from baseline was used to determine EULAR responses of good, moderate, or no response. For a post-baseline score ≤ 3.2, a change from baseline of < -1.2 was a good response, < -0.6 to ≥ -1.2 was a moderate response, and ≥ -0.6 was no response. For a post-baseline score > 3.2 to ≤ 5.1, a change from baseline of < -0.6 was a moderate response and ≥ -0.6 was no response. For a post-baseline score > 5.1, a change from baseline < -1.2 was a moderate response and ≥ -1.2 was no response. A good response could not be achieved for post-baseline scores > 3.2.

    Measured: Baseline to Week 24

  14. Change From Baseline in the Van Der Heijde Modified Sharp Radiographic Score at Week 24

    The degree of joint damage was assessed using the van der Heijde modified total Sharp score (mTSS). The methodology quantifies the extent of bone erosions for 44 joints and joint space narrowing (JSN) for 42 joints, with higher scores representing greater damage. The independent read of X-ray images was performed by 2 primary readers. In case of discrepancy between the 2 primary readers, an adjudicator was involved. The mTSS can range from 0 to 448 with a higher score indicating more joint damage. A negative change score indicates improvement.

    Measured: Baseline to Week 24

  15. Change From Baseline in the Physical and Mental Component Scores of the Short Form 36 (SF-36) Health Survey at Week 24

    The SF-36 Health Survey uses patient-reported symptoms on 8 subscales to assess health-related quality of life (HRQoL). The Physical Component Summary (PCS) score summarizes the subscales Physical Functioning, Role-Physical, Bodily Pain, and General Health. The Mental Component Summary (MCS) score summarizes the subscales Vitality, Social Functioning, Role-Emotional, and Mental Health. Each score was scaled from 0 to 100 with a higher score indicating better HRQoL. A positive change score indicates an improvement in HRQoL.

    Measured: Baseline to Week 24

  16. Change From Baseline in Hemoglobin at Week 24

    Measured: Baseline to Week 24

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 Nov 2010 (estimated)
  2. Study startMar 2011
  3. Primary completionMay 2012
  4. Study completionNov 2013

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Outcomes assessor
Enrolment
656 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01232569
Sponsor's protocol ID
NA25220
Other IDs
2010-019912-18
Status last verified
Jul 2015
First submitted
1 Nov 2010
Last updated
29 Jul 2015

Publications

  • Kivitz A, Olech E, Borofsky M, Zazueta BM, Navarro-Sarabia F, Radominski SC, Merrill JT, Rowell L, Nasmyth-Miller C, Bao M, Wright S, Pope JE. Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2014 Nov;66(11):1653-61. doi: 10.1002/acr.22384.

    PubMed 24942540

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Tocilizumab 162 mg in people with Rheumatoid Arthritis, run by Hoffmann-La Roche at 141 sites in 22 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 29 Jul 2015. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 141 sites in United States, Brazil, Russia, Mexico, Israel and 17 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 23 Oct 2013). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percentage of Patients With an American College of Rheumatology 20 (ACR20) Response at Week 24 (time frame: Baseline to Week 24). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01232569, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Jul 2015.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in